Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer

Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer

Conclusion: HER2 IHC 2+ may indicate a decreased tpCR rate, bpCR rate, and apCR rate to neoadjuvant treatment in HR-positive patients having HER2-positive breast cancer, but not in HR-negative patients.

Saved in:

Bibliographic Details
Main Authors:	Miaomiao Jia, Haibo Yang, Lihui Pan, Jinnan Gao, Fan Guo
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	The Breast Journal
Online Access:	http://dx.doi.org/10.1155/2024/8851703
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Concordance between Immunohistochemistry and Microarray Gene Expression Profiling for Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Statuses in Breast Cancer Patients in Lebanon
by: Ghina B. Fakhri, et al.
Published: (2018-01-01)

Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
by: Lothar Häberle, et al.
Published: (2025-01-01)

Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
by: Luca Mastrantoni, et al.
Published: (2025-02-01)

HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
by: Agnieszka Halon, et al.
Published: (2012-01-01)

The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
by: Sanaa Gamrani, et al.
Published: (2023-01-01)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

Trends in breast cancer among elderly women: Development in estrogen and HER2 subtypes in the last ten years
by: Frederik K. Palshof, et al.
Published: (2025-02-01)

Role of Fcγ receptors in HER2-targeted breast cancer therapy
by: Hope S Rugo, et al.
Published: (2022-01-01)

HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization
by: Cathy B. Moelans, et al.
Published: (2009-01-01)

Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
by: Femke A. I. Ehlers, et al.
Published: (2025-01-01)

Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study
by: Jin Liu, et al.
Published: (2022-01-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma
by: Roberto de Moraes Cordts Filho, et al.
Published: (2016-01-01)

Comparison between Real-Time Quantitative PCR Detection of HER2 mRNA Copy Number in Peripheral Blood and ELISA of Serum HER2 Protein for Determining HER2 Status in Breast Cancer Patients
by: Maria Savino, et al.
Published: (2009-01-01)

Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer
by: Solmaz AghaAmiri, et al.
Published: (2021-01-01)

Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors
by: Maria Antonietta Lucci, et al.
Published: (2010-01-01)

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01)

Surgical treatment after neoadjuvant systemic therapy for HER2-positive invasive breast cancer in the Netherlands: 10-Year trends and the influence an accompanying DCIS component
by: Roxanne A.W. Ploumen, et al.
Published: (2025-02-01)

Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation
by: Esin Oktay, et al.
Published: (2013-01-01)

Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer
by: Maria Elena Lacruz, et al.
Published: (2025-02-01)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
by: Andrea L. A. Wong, et al.
Published: (2012-01-01)

A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer
by: Wei Lv, et al.
Published: (2018-01-01)

Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients
by: Ovidiu Balacescu, et al.
Published: (2016-01-01)

To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma
by: Anuja Yadav, et al.
Published: (2023-07-01)

‘Her Room Was Her World’: Nellie Sloggett and North Cornish Folklore
by: Simon Young
Published: (2017-12-01)

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
by: Nu T. Lu, et al.
Published: (2015-09-01)

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01)

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
by: Hanghang Ma, et al.
Published: (2025-02-01)

Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
by: Tryambak Pratap Srivastava, et al.
Published: (2025-01-01)

Predictive factors for axillary pathological complete response to neoadjuvant therapy in elderly breast cancer patients
by: Yuying Wang, et al.
Published: (2025-01-01)

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
by: Abul Azad, et al.
Published: (2025-01-01)

Her mistletoe miracle
by: FOx Roz Denny
Published: (2008)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01)

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study
by: Fei Wang, et al.
Published: (2025-01-01)

Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
by: Claire Corcoran, et al.
Published: (2025-01-01)

Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation
by: Farnaz Khaleseh, et al.
Published: (2021-05-01)

HER2-Positive Metaplastic Spindle Cell Carcinoma Associated with Synchronous Bilateral Apocrine Carcinoma of the Breast
by: Katsumi Kito, et al.
Published: (2014-01-01)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
by: Sara M Tolaney, et al.
Published: (2022-10-01)

A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management
by: Xinpei Deng, et al.
Published: (2024-09-01)